AbbVie Inc. $ABBV Shares Acquired by Nordwand Advisors LLC

Nordwand Advisors LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 9,478.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,166 shares of the company’s stock after purchasing an additional 45,684 shares during the period. AbbVie accounts for about 1.4% of Nordwand Advisors LLC’s investment portfolio, making the stock its 15th largest holding. Nordwand Advisors LLC’s holdings in AbbVie were worth $8,569,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in AbbVie by 0.5% during the first quarter. Vanguard Group Inc. now owns 173,917,865 shares of the company’s stock worth $36,439,271,000 after acquiring an additional 845,787 shares during the period. Geode Capital Management LLC lifted its holdings in AbbVie by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after acquiring an additional 924,761 shares during the last quarter. Northern Trust Corp boosted its position in shares of AbbVie by 0.9% during the 1st quarter. Northern Trust Corp now owns 22,013,920 shares of the company’s stock valued at $4,612,357,000 after purchasing an additional 189,294 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of AbbVie by 31.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock worth $3,068,820,000 after purchasing an additional 3,519,187 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of AbbVie by 5.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 12,771,854 shares of the company’s stock worth $2,675,959,000 after purchasing an additional 713,148 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

Shares of AbbVie stock opened at $234.01 on Tuesday. AbbVie Inc. has a 12 month low of $163.81 and a 12 month high of $244.81. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The stock has a market cap of $413.59 billion, a PE ratio of 111.44, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The business has a fifty day simple moving average of $225.37 and a 200-day simple moving average of $204.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the company posted $3.00 EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s payout ratio is presently 524.24%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ABBV shares. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price for the company. in a research note on Tuesday, November 4th. HSBC set a $225.00 price objective on AbbVie in a research report on Thursday, October 2nd. Scotiabank began coverage on AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price on the stock. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and upped their target price for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. Finally, Citigroup dropped their price target on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $240.14.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.